The present application relates to a conjugate for targeting an agent, such as a therapeutic or diagnostic agent, to tissues in vivo. In particular, it relates to conjugates for targeting the extracellular matrix (ECM) of tissues, particularly tumour neovasculature, and to therapeutic use of such conjugates in the treatment of a disease/disorder, such as cancer. In particular the application relates to immunocytokines for targeting interleukin-2 (IL2) to ECM components associated with neoplastic growth and/or angiogenesis.
